Reata Hopes To Beat Competition To Market With Abbott Deals
This article was originally published in The Pink Sheet Daily
Executive Summary
Reata Pharmaceuticals hopes the strength of its partnerships and intellectual property will allow it to get an edge on a hot market.
You may also be interested in...
Abbott Spin-Off AbbVie To Remain Close To Its Roots
Abbott announces that its research-based pharmaceutical division will be called AbbVie once it splits off at the end of the year.
Abbott Pays $400 Million Upfront For Reata’s Preclinical AIM Programs
Adding on to the two companies’ collaboration around chronic kidney disease candidate bardoxolone, Abbott will pay a record upfront for preclinical assets to co-develop and co-commercialize Reata’s antioxidant inflammation modulators in a variety of disease areas.
Reata Readies Bardoxolone For Phase III Looking At Kidney Function Outcomes
Further Phase II data show biomarker evidence, and Reata will now look to a 1,600-patient Phase III trial to prove the drug can lead to improved kidney function.